Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Randomized, Open-label, Multi-center, Global Study of MEDI4736 Alone or in Combination With Tremelimumab Versus Standard of Care in the Treatment of First-line Recurrent or Metastatic Squamous Cell Head and Neck Cancer Patients

NCT02551159 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT02551159
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02551159 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Randomized, Open-label, Multi-center, Global Study of MEDI4736 Alone or in Combination With Tremelimumab Versus Standard of Care in the Treatment of First-line Recurrent or Metastatic Squamous Cell Head and Neck Cancer Patients
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
October 15, 2015
Completion date
May 21, 2021
Enrollment
823 (actual)
Sites
197

Conditions

As the registry lists them; a condition with its own page is linked.

squamous cell carcinoma of the head and neck